Jeffrey Wishik
Neurology · Providence, RINPI 1447305636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,640 of the $34,404 with a category attached, or 68.7%. Ironshore Pharmaceuticals Inc. accounts for 81.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $28,658 and has fallen 99.5% since, to $150 in 2025.
Across 240 payments — averaging $143.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$28K
- Corium, LLC$3K
- AbbVie$776
- Takeda Pharmaceuticals U.S.A., Inc.$363
- Neos Therapeutics, LP$260
- Eisai Inc.$221
- plus $2K from 18 others
What the payments were for
- Consulting fees$3601%
- Speaking & faculty fees$23,64069%
- Travel & lodging$4,07012%
- Food & beverage$6,33518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 73 | $28,093 |
| Corium, LLC | 44 | $2,758 |
| AbbVie | 34 | $776 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $363 |
| Neos Therapeutics, LP | 14 | $260 |
| Eisai Inc. | 2 | $221 |
| Amgen | 2 | $202 |
| Shire North American Group Inc | 16 | $202 |
| Medtronic | 1 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $181 |
| Biohaven Pharmaceuticals, Inc. | 4 | $180 |
| CSL Behring | 1 | $125 |
| AstraZeneca | 1 | $114 |
| Acadia Pharmaceuticals Inc | 1 | $110 |
| Supernus Pharmaceuticals, Inc. | 6 | $106 |
| Pfizer | 5 | $105 |
| Sanofi | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 1 | $81 |
| UCB, Inc. | 1 | $78 |
| Tris Pharma Inc | 3 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $40 |
| Johnson & Johnson | 2 | $39 |
| Noven Therapeutics, LLC | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$26,826
- Azstarys$2,148
- NURTEC ODT$240
- Fycompa$221
- PERCEPT PC BRAINSENSE$181
- Hizentra$125
- AIMOVIG$125
- UBRELVY$122
- ULTOMIRIS$114
- NUPLAZID$110
- AUBAGIO$100
How this compares
$34,404 in reported general payments places this provider in the 85th percentile of 86 neurology providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 135 | $4,241 |
| Lisdexamfetamine Dimesylate | 20 | $3,683 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 14 | $2,222 |
| Duloxetine Hcl | 17 | $924 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 22 | $859 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $746 |
| Quetiapine Fumarate | 12 | $332 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $301 |
| Methylphenidate Hcl | 21 | $243 |
| Bupropion XlBupropion Hcl | 13 | $212 |
| Lorazepam | 14 | $82 |
| Alprazolam | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other neurology in Providence
- Stephen SallowayProvidence$329K
- Syed RizviProvidence$160K
- John EastonProvidence$112K
- Saima ChaudhryProvidence$90K
- Monica DhakarProvidence$45K
- Prathana PrakashProvidence$31K
- Karen FurieProvidence$29K
- Chuang WuProvidence$14K
- Emily WeisbachProvidence$11K
- Shawn TsekhanProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.